Zheng Quan Shi Bao Wang·2026-01-15 00:54Company Overview - Yinuo Medical has submitted a listing application to the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors [1] - The company focuses on the discovery, development, production, and commercialization of novel oncolytic immunotherapies and engineered exosome therapies [1] Product Pipeline - The product pipeline includes two oncolytic immunotherapy products and five engineered exosome products [1] - The core product, MVR-T3011, is a phase II oncolytic immunotherapy product based on herpes simplex virus type 1 (HSV-1), combining tumor lysis with anti-PD-1 antibody and IL-12 expression [1] - MVR-T3011 is being evaluated as a monotherapy and in combination therapies for a range of indications including bladder cancer, head and neck squamous cell carcinoma, and other solid tumors [1] Market Potential - The global oncolytic immunotherapy market is projected to grow from $87.1 million in 2024 to $1.56 billion by 2028, representing a compound annual growth rate (CAGR) of 105.7% [1] - By 2033, the market is expected to further expand to $17.145 billion [1] - The Chinese oncolytic virus drug market is anticipated to grow from $6.3 million in 2024 to $22.3 million by 2028, with a CAGR of 143.9% [1] - By 2033, this market is expected to reach $327.1 million [1]